
BiomX extends IBD collaboration with Boehringer Ingelheim
Microbiome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD).
Microbiome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD).